Epidermal Growth Factor Receptor (EGFR) and its Cross-Talks with Topoisomerases: Challenges and Opportunities for Multi-Target Anticancer Drugs

摘要: Background: The interactions of Epidermal Growth Factor Receptor (EGFR) and topoisomerases have been seen in various cancer including brain, breast, ovarian, colorectal, gastric, etc. Methods: studies adenocarcinoma patients, chromogenic situ hybridization, western blotting, receptor binding assay electromobility shift assays, threw light on the biophysical biochemical features EGFR Topoisomerase cross-talks. Results: It has been revealed that both isomers topoisomerase (Topo I Topo II) interact via different mechanisms with EGFR. II HER2 share same location i.e. 17q12–21 regions which could be a possible cause predominant between them. are mechanically related to nucleolar translocation heparenase by EGF c-Jun. Conclusion: We compiled literature findings mechanistic interventions, signaling pathways, patents, vitro vivo data tested inhibitors and combinations clinical trials, provide convincing confirmations for topoisomerases. These may be used deriving consistent route mechanism, design development standard drug and dual or multi inhibitors.